Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
AnaptysBio: Upside Constrained By Undifferentiated Data, Legal Uncertainties [Seeking Alpha]
Assessing AnaptysBio (ANAB) Valuation After New US$100 Million Buyback And Cancelled Equity Offerings [Yahoo! Finance]
AnaptysBio (ANAB) had its price target raised by Piper Sandler from $67.00 to $95.00. They now have an "overweight" rating on the stock.
AnaptysBio (ANAB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $66.00 price target on the stock.